Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Investigating the Role of Hepatic Glucagon Receptor Signaling in Healthspan and Aging

Award Number: R01AG079924
ORGANIZATION: NATIONAL INSTITUTE ON AGING
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/15/2024
PERIOD OF PERFORMANCE END DATE: 03/31/2029

Group Awards By:

View Award Description

Investigating the Role of Hepatic Glucagon Receptor Signaling in Healthspan and Aging - Project Summary: Obesity and type 2 diabetes mellitus accelerate aging shortening the duration of healthspan. Conversely, chronic calorie restriction extends healthspan. Most research aimed at understanding the mechanism by which calorie restriction slows aging has focused on insulin and downstream signaling cascades. Similarly, the accelerated aging in type 2 diabetes is largely attributed to dysfunctional insulin signaling. Glucagon, a hormone that counter-regulates insulin, is commonly affected by these same interventions. We have shown that glucagon receptor deletion decreases median lifespan by 35% in normal weight mice. Glucagon receptor deletion shortens lifespan to a greater degree in diet induced obese mice and prevents the extension in lifespan resulting from calorie restriction. This proposes that the hyperglucagonemia in obesity may be protective against obesity accelerated aging and that glucagon is essential for calorie restriction to extend lifespan. Although the role of glucagon receptor signaling in aging has not been heavily investigated, the rigor of this work is supported by known effects of glucagon on downstream messengers that extend healthspan. Both AMPK activity and cyclic AMP are established mediators that extend healthspan. Glucagon activates AMPK and increases cAMP. Highlighting the significance of this proposal, Glucagon receptor agonists are entering the market for the treatment of diabetes and obesity. To understand the potential impact of these agonists, we propose to study the role of glucagon receptor signaling in normal aging, the accelerated aging in obesity, and the slowed aging resulting from calorie restriction. We propose 2 aims that focus on genetic (Aim 1) and pharmacological (Aim 2) manipulation to increase glucagon receptor signaling. We will combine these models with dietary models of obesity and calorie restriction and with genetic models of normal glucagon receptor signaling and glucagon receptor knockout to better understand the role of glucagon receptor signaling in normal aging, obesity accelerated aging, and the slowed aging resulting from calorie restriction. We have established that glucagon is integral in extending lifespan in calorie restriction and maintaining lifespan in obesity. We appreciate that insulin plays a key role in aging, but also recognize that pharmacologically targeting insulin signaling is limited because of the key role of insulin in glucose homeostasis. Conversely, glucagon receptor agonists are safe. In turn, this research provides a unique opportunity to identify a new, therapeutically viable target to extend healthspan and lifespan.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $603,657 )
2026	2026	UNIVERSITY OF ARIZONA	845 N PARK AVE RM 538	TUCSON	AZ	85721	PIMA	USA	Aging Research	000	3	5/8/2026	NON-COMPETING CONTINUATION	$603,657
														Subtotal = $603,657

Issue Date FY: 2025 ( Subtotal = $548,858 )
2025	2025	UNIVERSITY OF ARIZONA	845 N PARK AVE RM 538	TUCSON	AZ	85721	PIMA	USA	Aging Research	000	2	4/7/2025	NON-COMPETING CONTINUATION	$504,054
2025	2025	UNIVERSITY OF ARIZONA	845 N PARK AVE RM 538	TUCSON	AZ	85721	PIMA	USA	Aging Research	001	2	6/13/2025	NON-COMPETING CONTINUATION	$44,804
														Subtotal = $548,858

Issue Date FY: 2024 ( Subtotal = $198,065 )
2024	2024	UNIVERSITY OF ARIZONA	845 N PARK AVE RM 538	TUCSON	AZ	85721	PIMA	USA	Aging Research	000	1	9/3/2024	NEW	$198,065
														Subtotal = $198,065

Grand Total All Awards = $1,350,580

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Investigating the Role of Hepatic Glucagon Receptor Signaling in Healthspan and Aging

Award Number: R01AG079924

ORGANIZATION: NATIONAL INSTITUTE ON AGING

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/15/2024

PERIOD OF PERFORMANCE END DATE: 03/31/2029

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer